Ignite Creation Date:
2024-07-17 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06482164
Status:
RECRUITING
Last Update Posted:
2024-07-01
First Post:
2024-06-25
Brief Title:
The THINK Study Incidence of Neurotrophic Keratopathy
Sponsor:
Research Insight LLC
Organization:
Research Insight LLC
Study Overview
Official Title:
The THINK Study Testing Hypoesthesia and the Incidence of Neurotrophic Keratopathy
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
THINK
Brief Summary:
The study purpose is to evaluate corneal sensitivity in patients that have Stage 1 Neurotrphic Keratopathy NK Identifying patients with Stage 1 NK may predict those who will in the future require rhNGF for optimal visual performance
Detailed Description:
The purpose of this study is to evaluate corneal sensitivity in a cross-section of patients with signs of dry eye disease DED correlating findings against clinical parameters relating to the severity of disease and impact on quality of vision Identifying those patients with Stage 1 Neurotrophic Keratopathy NK ie those with corneal staining and reduced sensitivity may predict those who will in the future require rhNGF for optimal visual performance
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None